Activity from announced rounds
Gaingels co-invests alongside venture leads in companies committed to diverse and inclusive teams, spanning seed through growth and pre-IPO rounds across technology, healthcare and consumer markets.
Its investor community includes LGBTQ+ people and allies, extending representation within the ownership of venture-backed companies. Portfolio companies work with its Gaingels Letter commitments and Venture Inclusion programme on building more inclusive organisations.
A board access programme provides free recruitment advice for diverse board members and observers. This gives founders a practical governance resource alongside a co-investment partner for a round led by another venture firm.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.